Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Fiche publication
Date publication
février 2016
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Pr WESTEEL Virginie
Tous les auteurs :
Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O
Lien Pubmed
Résumé
HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1-2% of lung adenocarcinomas. There is, to date, no standard of care for these patients. We thus aim to study the therapeutic outcomes of patients harboring HER2 mutations and establish the efficacy of various drug regimens.
Mots clés
Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cohort Studies, Disease-Free Survival, Europe, Female, Humans, Lung Neoplasms, drug therapy, Male, Middle Aged, Molecular Targeted Therapy, methods, Quinazolines, therapeutic use, Quinolines, therapeutic use, Receptor Protein-Tyrosine Kinases, genetics, Receptor, Epidermal Growth Factor, genetics, Receptor, ErbB-2, genetics, Retrospective Studies, Trastuzumab, therapeutic use, Treatment Outcome
Référence
Ann. Oncol.. 2016 Feb;27(2):281-6